Mexidol, 0.125 g, 30 pcs.

Coated tablets from white to white with a creamy shade, round, biconvex.

1 tablet contains:

Active ingredients :

ethylmethylhydroxypyridine succinate 125 mg.

Excipients:

lactose monohydrate,

sodium carboxymethyl cellulose (carmellose sodium),

magnesium stearate.

Shell composition:

opadray II white (macrogol (polyethylene glycol),

polyvinyl alcohol,

talc,

titanium dioxide).

In a blister strip packaging 10 tablets.

In a carton package there are 3 or 5 blisters.

Antioxidant.

Pharmacodynamics

Mexidol® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accidents, alcohol and antipsychotic drugs (neuroleptics) intoxication).

The mechanism of action of Mexidol® is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structural and functional organization of biomembranes and transport of neuromembranes.

Mexidol® increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.

The antistress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wakefulness cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.

Mexidol® has a pronounced antitoxic effect in withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disturbances, autonomic functions, and is also able to relieve cognitive impairment caused by prolonged intake of ethanol and its withdrawal. Under the influence of Mexidol®, the effect of tranquilizing, neuroleptic, antidepressant, hypnotic and anticonvulsants is enhanced, which allows them to reduce their doses and reduce side effects. Mexidol® improves the functional state of the ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity.

Pharmacokinetics

Suction

With the introduction of Mexidol in doses of 400-500 mg, Cmax in plasma is 3.5-4.0 μg / ml and is achieved within 0.45-0.5 hours.

Distribution

After i / m administration, the drug is determined in blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 hours.

Withdrawal

It is excreted from the body in the urine mainly in glucuronoconjugated form and in small quantities - unchanged.

• consequences of acute disorders of cerebral circulation, including after transient ischemic attacks, in the phase of subcompensation as preventive courses;

• minor traumatic brain injury, the consequences of traumatic brain injury;

• encephalopathy of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed);

• vegetative dystonia syndrome;

• mild cognitive disorders of atherosclerotic genesis;

• anxiety disorders in neurotic and neurosis-like states;

• conditions after acute intoxication with antipsychotic drugs;

• asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;

• exposure to extreme (stress) factors. 

• ischemic heart disease as part of complex therapy;

• relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders

There have not been strictly controlled clinical studies of the safety of using Mexidol® during pregnancy and lactation.

Contraindication to the use of Mexidol is:

• acute liver failure;
• acute renal failure;
• hypersensitivity to the drug.

Due to insufficient knowledge of the drug action:

• childhood;
• pregnancy;
• lactation (breastfeeding) period.

When using the drug, the following are possible:

From the side of the digestive system: the appearance of individual side reactions of a dyspeptic or dyspeptic nature is possible.

Others: Allergic reactions are possible.

When used together, Mexidol® enhances the effect of benzodiazepine derivatives, antidepressants, anxiolytics, antiparkinsonian and anticonvulsants.

Mexidol® reduces the toxic effect of ethanol.

Method of administration and dosage regimen depending on symptoms

Inside, 125-250 mg 3 times / day; the maximum daily dose is 800 mg (6 tab.). Duration of treatment is 2-6 weeks; for relief of alcohol withdrawal - 5-7 days. The treatment is stopped gradually, reducing the dose over a period of 2-3 days.

The initial dose is 125-250 mg (1-2 tablets) 1-2 times / day with a gradual increase until a therapeutic effect is obtained; the maximum daily dose is 800 mg (6 tab.).

The duration of the course of therapy in patients with coronary artery disease is at least 1.5-2 months. Repeated courses (on the recommendation of a doctor) should preferably be carried out in the spring-autumn periods.

In case of an overdose, drowsiness may develop.

Precautions when taking the drug

Mexidol® can be combined with all drugs used to treat somatic diseases.

Use in pediatrics

Mexidol® is not prescribed for children due to insufficient knowledge of the drug's action.

Influence on the ability to drive vehicles and other mechanisms that require increased concentration of attention

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Interaction with alcohol

Mexidol® reduces the toxic effect of ethanol.

Terms of dispensing from pharmacies

The drug is available by prescription.

pills